

The information in the press release is intended for investors.

Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)

GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 8, 2024.

The shareholders in Isofol Medical AB (publ), Reg. No. 556759-8064, with its registered office in Gothenburg, are hereby invited to attend the annual general meeting held on Wednesday, May 8, 2024 at 2 p.m. at Biotech Center, Arvid Wallgrens backe 20, Fl. 5, Gothenburg, Sweden. Registration at the annual general meeting starts at 1:30 p.m. and ends when the meeting convenes.

The complete notice to attend is available in Swedish on the company's website, www.isofolmedical.com

For further information, please contact

Isofol Medical AB (publ)
Magnus Hurst, CFO
E-mail: magnus.hurst@isofolmedical.com
Telephone: +46 (0)738 73 34 18

The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CEST on April 5, 2024.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com